NCT05177718View on ClinicalTrials.gov

Natalizumab and Chronic Inflammation

PHASE4TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

September 16, 2022

Primary Completion Date

April 5, 2023

Study Completion Date

April 5, 2023

Conditions

Multiple Sclerosis

Interventions

DRUG

Natalizumab 300 MG in 15 ML Injection

Disease modifying agent

Trial Locations (1)

37215

Vanderbilt University Medical Center, Nashville

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Biogen

INDUSTRY

lead

Vanderbilt University Medical Center

OTHER